1222106-43-5Relevant academic research and scientific papers
Preparation method of 4,7-diazaspiro[2.5]octane derivative
-
Paragraph 0034; 0060; 0073; 0080; 0081; 0082, (2018/12/13)
The invention provides a preparation method of 4,7-diazaspiro[2.5]octane derivative. The 4,7-diazaspiro[2.5]octane derivative is prepared by taking 1-aminocyclopropane carboxylate as a starting material. The preparation method has the advantages of simple operation steps, stable process conditions, high controllability, high product yield (the four-step reaction yield of compounds shown as formulas II to I can be up to 70 percent), environmental friendliness and the like, and is suitable for large-scale production.
PROCESS FOR THE PREPARATION OF CYCLOPROPYLDIKETOPIPERAZINES AND OF A KEY INTERMEDIATE OF DS-5272
-
Paragraph 00143; 00153, (2018/09/08)
Object of the present invention is an improved process for the preparation of cyclopropyldiketopiperazines and thereof key intermediates.
Sulfamide derivative and application thereof
-
Paragraph 0178; 0179, (2017/08/29)
The invention relates to a sulfamide derivative and a pharmaceutical composition comprising the compound as well as use of the sulfamide derivative and the pharmaceutical composition as a preparation drug, in particular, use of a drug for preparing a BCL-2 family protein antagonist and use of the drug for treating cancers.
IMIDAZOTHIAZOLE DERIVATIVE HAVING PROLINE RING STRUCTURE
-
Page/Page column 55; 56, (2011/11/07)
[Problem to be Solved] There is provided a novel compound that inhibits interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity. [Solution] The present invention provides an imidazothiazole derivative rep
MORPHOLINOPURINE DERIVATIVES
-
Page/Page column 154, (2010/06/14)
There is provided a novel compound that inhibits phosphatidylinositol 3-kinase (PI3K) and/or the mammalian target of rapamycin (mTOR) and exhibits anti-tumor activity. The present invention provides a compound represented by the following formula (1) having various substituents that inhibits PI3K and/or mTOR and exhibits anti-tumor activity: wherein R1, R2, R3, R4, Ra, Rb, Rc, and X each have the same meaning as defined in the specification.
